STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER: STENO
STENOCARE A/S ("STENOCARE") today announces its results for the period 01.01.2026 - 31.03.2026. The report, which has not been reviewed by the Company's auditors, is attached to this release and is also available on https://stenocare.com/investor-relations/
Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments:
" Stenocare delivered a strong performance in Q1 2026, marked by solid growth in net sales, a positive EBITDA, and increasing traction in Germany. The integration of CannGros has been successfully completed, confirming the strategic rationale behind the acquisition."
| (KDKK) | 01.01.2026 31.03.2026 3 months | 01.01.2025 31.03.2025 3 months | 01.01.2025 31.12.2025 12 months | |
| Net sales | 3,003 | 782 | 7,021 | |
| Operating profit before depreciation (EBITDA) | 61 | -1,832 | -1,742 | |
| Net financial items | -120 | -182 | -423 | |
| Result per share (DKK) | -0.01 | -0.05 | -0.06 | |
| Solidity (%) | 76 | 26 | 75 | |
Result per share: The result for the period divided by the average number of shares. Total number of shares as of March 31, 2026, amounted to 43,403,745 (38,403,745). Average number of shares for the first quarter 2026 was 43,403,745 (38,403,745).
Solidity: Equity divided by total capital.
On the annual general meeting held April 29, 2026, it was decided to merge Stenocare A/S and CannGros ApS as per January 1, 2026, with Stenocare A/S as the continuing company. The 2026 numbers include Stenocare A/S and CannGros ApS. The numbers for 2025 reflect the operations of Stenocare A/S alone.
Comments to the report